Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9038640 | 0.84 | TTR (0.48) | PKMTPMTPOLBHSD17B10SMN1; SMN2 | |
| SCHEMBL9040995 | 0.81 | PKM (0.55) | PKMTPMTL3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL31401211 | 0.81 | VCAM1 (0.44) | L3MBTL1POLBHSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL26970030 | 0.81 | ACLY (0.41) | TPMTSMN1; SMN2KMT2ATTRLMNA | |
| SCHEMBL9041431 | 0.81 | CDC25B (0.46) | PKMTPMTPOLBHSD17B10SMN1; SMN2 | |
| SCHEMBL4507939 | 0.80 | TPMT (0.54) | TPMTHSD17B10SMN1; SMN2TTRLMNA | |
| SCHEMBL31401376 | 0.79 | TTR (0.47) | PKMTPMTL3MBTL1POLBHSD17B10 | |
| SCHEMBL7826598 | 0.76 | VCAM1 (0.49) | TPMTPOLBKMT2ALMNA | |
| SCHEMBL9042697 | 0.75 | TTR (0.47) | PKMTPMTPOLBHSD17B10SMN1; SMN2 | |
| SCHEMBL31401501 | 0.75 | HDAC1 (0.42) | PKMTPMTHSD17B10SMN1; SMN2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |